British American Tobacco is a medium-term Buy as combustibles keep generating cash while smokeless products, led by Velo, show real operating momentum. The stock looks reasonably valued with a fair value estimate of $68.
British American Tobacco(BTI) is a medium-term Buy for balanced, moderate-risk investors because the company still throws off large cash flow from combustibles while its smokeless portfolio is finally showing real operating traction. FY2025 revenue was £25.610bn, down 1.0% reported but up 2.1% at constant currency, and adjusted diluted EPS rose 3.4% with results landing at the top end of guidance. That is not a hyper-growth story. It is a transition story, and the transition is getting more credible.
The core bull case rests on three named facts. First, BAT added 4.7m smokeless consumers in 2025, bringing the total to 34.1m. Second, New Categories revenue grew 7% in 2025, with Modern Oral up 48% and category contribution reaching £442m. Third, the legacy engine remains highly profitable: gross margin was 82.7%, operating margin was 34.6%, net margin was 30.3%, and free cash flow was $6.893bn on the core cash flow dataset.
The main reason the stock is not an easy A-grade compounder is equally clear. BAT still carries $35.07bn of debt against $3.843bn of cash, leaving net debt of $31.227bn. Reported revenue growth is thin, analyst EPS estimates for 2026 through 2029 trend lower than trailing EPS on the supplied dataset, and the tobacco industry remains under constant regulatory and litigation pressure. This is a cash-rich ship still carrying heavy cargo.
At roughly 12.6x trailing earnings and 12.2x forward earnings, BTI does not look expensive for a company with a 5.49% free cash flow yield, a 25-year dividend growth record, a planned £1.3bn 2026 buyback, and management guidance for 2026 revenue growth of 3% to 5%, adjusted profit from operations growth of 4% to 6%, and adjusted diluted EPS growth of 5% to 8%, albeit at the lower end. That mix supports a fair value estimate of $68, with upside driven by execution in Velo, Vuse, and glo rather than multiple expansion alone.
The brand portfolio is broad and unusually resilient. BAT owns global and regional names including Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, Camel Snus, Vogue, Viceroy, Kool, Peter Stuyvesant, Craven A, and State Express 555. In tobacco, brand equity is not a cosmetic asset. It is shelf space, pricing power, and retention wrapped into one.
BAT’s current strategy is to use the cash generation of combustibles to fund a transition toward smokeless products. According to FY2025 business context, combustibles represented 84.1% of revenue and New Categories represented 11.7% of revenue. Management’s longer-term ambition is to become a predominantly smokeless business by 2035, with 50% of revenue from non-combustibles by that year and 50m smokeless consumers by 2030.
That strategic pivot matters because the company’s financial profile has already started to reflect it. BAT delivered FY2025 profit from operations of £9,997m versus £2,736m in 2024, adjusted diluted EPS growth of 3.4%, and adjusted net debt to adjusted EBITDA of 2.55x at year-end 2025. The old business still funds the machine, but the newer businesses are no longer just science projects.
BAT reports its business through both product categories and regions. On the product side, the supplied FY2025 segment data show Combustibles revenue of $20.201bn, or 91.9% of the listed segment total, Traditional Oral revenue of $1.043bn, or 4.7%, and Others revenue of $745m, or 3.4%. Separate company disclosures add the missing strategic layer: New Categories represented 11.7% of FY2025 revenue, with combustibles at 84.1%.
Combustibles remain the economic backbone. In 2025, combustible revenue grew 1% despite volume decline, with price/mix more than offsetting lower units. In the U.S., combustible revenue rose 4.6%, value share increased 30 basis points, and overall U.S. revenue increased 5.5% with adjusted profit up 5.9%. That is exactly what BAT needs from its legacy portfolio: stable to modestly growing cash generation while the portfolio mix shifts.
New Categories are where the strategic value is building. Management said New Categories revenue grew 7% in 2025, driven by Modern Oral growth of 48%, while heated products rose 1% and vapour declined nearly 9% due to illicit pressure in the U.S. and Canada. Category contribution reached £442m, and management said new category contribution was up 77% at constant rates. That is a meaningful profitability inflection, not just a top-line headline.
Regionally, BAT’s footprint gives it both diversification and complexity. In HY2025 adjusted profit from operations at constant FX and adjusted for Canada, the U.S. delivered £3,150m, AME delivered £1,386m, and APMEA delivered £899m. The U.S. and AME carried the year, while APMEA faced fiscal and regulatory headwinds, especially in Bangladesh and Australia. The portfolio is global, but the earnings power is not evenly distributed.
The medium-term question is whether New Categories can become large enough to offset the structural decline in combustibles without destroying margins. FY2025 offered a better answer than prior years. New Categories returned to double-digit revenue growth in the second half, category contribution improved, and management guided to low double-digit New Category revenue growth in 2026 led by Velo globally.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
BAT’s flagship reduced-risk product today is Velo, particularly Velo Plus in the U.S. Management called Velo Plus the fastest-growing Modern Oral brand in the largest Modern Oral value pool globally. Since launch at the end of 2024, it reached the #2 position in both volume and value share, gaining nearly 18 percentage points of volume share and nearly 14 points of value share.
The operating metrics behind that claim are unusually strong. BAT said Velo Plus more than doubled its consumer base, drove over 300% Modern Oral revenue growth, captured around 70% of industry volume growth and 80% of industry value growth in December, and maintained a repurchase rate of around 70% throughout the year. In the HY2025 investor deck, Velo Plus also showed an 8.7 percentage point volume share gain from Nov. 2024 to May 2025 and was heading toward the #2 U.S. Modern Oral brand position.
This matters because modern oral looks like BAT’s cleanest growth lane. The company said the total U.S. Modern Oral category had already overtaken the size of the legitimate vapour category at over £2bn of revenue in 2025. BAT also said it reached global volume share leadership in Modern Oral across top markets representing around 90% of total industry revenue. In plain English, Velo is becoming a real platform, not a niche add-on.
Vuse remains a major asset, but a more complicated one. Vuse Ultra launched in Canada in June 2025 and early results showed value share gains of 2.4 points in the investor deck, while management later cited nearly 80 basis points in Canada, close to 4 points in Germany, and above 2 points in France. Vuse returned to revenue growth in the second half of 2025, helped by enforcement activity and a competitor exit, but vapour still faces illicit-product pressure in the U.S. and Canada.
glo is BAT’s heated product platform. glo Hilo is the premium push, while next-generation glo HYPER is aimed at the value-for-money segment. Management said glo Hilo generated early volume share momentum in Japan, Poland, and Italy, with trial-to-retention rates of around 50%. That is promising, though heated products remain the least proven of BAT’s three major reduced-risk pillars.
BAT’s moat still starts with old-world strengths: brands, distribution, regulatory know-how, and cash flow. But the more interesting question is whether those strengths transfer into reduced-risk categories. FY2025 suggests they do, at least in modern oral and selected vapour markets.
The strongest evidence is in Velo. Management said Velo is already the clear European leader, around 6x larger than its nearest competitor. Velo Shift, launched in Sweden after a successful pilot, adds a premium design, five sensory flavors, and a differentiated hexagonal can. The product trades at a premium to the core Velo range and is already driving incremental share in launched channels. That is textbook premiumization: better product, better shelf signal, better pricing.
Innovation is also becoming more disciplined financially. Since 2021, BAT said it has driven a £1.4bn improvement in category contribution across New Categories. In 2025 alone, New Categories gross profit was up more than £200m and category contribution reached £442m. The company is no longer buying growth at any price. It is pruning markets, reallocating resources, and focusing on higher-return launches.
BAT’s competitive advantage in tobacco is often less glamorous than investors want, but more durable than they admit. Retail relationships, tax management, compliance systems, and route-to-market scale are hard to replicate. In the U.S., management tied Velo Plus success not just to product quality but to consumer insights, branding, digital analytics, and distribution enabled by Reynolds. That is the kind of infrastructure advantage that tends to show up in share gains before it shows up in valuation multiples.
The weak spot is that BAT is not the smoke-free leader globally. Industry context shows Philip Morris International(PMI) derived about 43% of Q1 2026 net revenues from smoke-free products, a much higher mix than BAT’s 11.7% New Categories revenue share in FY2025. BAT has innovation, but it is still playing catch-up in portfolio mix. That keeps the stock in the value camp rather than the premium-growth camp.
BAT’s operating model is built for scale and margin defense. The company absorbed around £300m of inflationary cost increases in 2025, plus transactional FX headwinds, while keeping group operating margin broadly flat at 44% on management’s adjusted basis. On the supplied profitability dataset, operating margin was 34.58% and gross margin was 82.7%, which confirms the core economics remain unusually strong.
Productivity is a major part of the story. Management said BAT has delivered £1.2bn in productivity savings since 2023 and is targeting a further £2bn by 2030. On top of that, the Fit2Win program is expected to deliver £600m of annualized incremental savings by 2028, with around £500m expected by 2027. Associated costs are expected to total around £600m over two years, with about £500m treated as adjusting items.
That cost program matters because it gives BAT room to fund innovation without blowing up margins. Management explicitly said the savings help offset inflation and FX while funding launches in Vuse Ultra, glo Hilo, and Velo Shift. In a declining-volume industry, productivity is not optional. It is the gearbox between pricing power and shareholder returns.
Supply chain exposure is global, and so are the friction points. BAT cited transactional FX headwinds driven primarily by Turkey, Japan, and Nigeria. It also flagged fiscal and regulatory headwinds in Bangladesh and Australia, which reduced total group revenue by around 1% and group adjusted profit from operations by around 2% in 2025. That is the trade-off of global diversification: no single market defines the company, but many markets can nick the edges.
Capacity investment is also following demand signals. Management said it is increasing capacity to support sustainable growth in modern oral and highlighted Velo Max as a higher-moisture product planned for the U.S. in 2026. When a tobacco company adds capacity in a reduced-risk category while still deleveraging, that is a sign of confidence backed by cash rather than optimism backed by slides.
The global tobacco and nicotine market remains enormous, but its growth profile is split. Market research in the supplied context estimates the broader tobacco market at $844.1bn in 2024 and points to roughly 4% CAGR through 2029, while the cigarettes market alone is expected to grow only around 2.25% CAGR through 2031. The volume story is weak. The pricing and mix story is where the money is.
WHO data show adult current tobacco use fell from 33.1% in 2000 to 19.5% in 2024, though the world still has about 1.3bn tobacco users. That is the central industry paradox: the user base is shrinking as a percentage of population, but the absolute pool remains massive. For incumbents like BAT, that supports continued cash generation in combustibles even as the long-term direction points lower.
The more attractive market is smoke-free nicotine. BAT says only 10% of the world’s 1bn smokers currently use New Category products, and it reported 34.1m smokeless consumers at FY2025. That leaves a large conversion pool. The investable issue is not whether the addressable market exists. It does. The issue is which companies can convert users profitably under regulation.
For BAT, modern oral currently looks like the best-positioned category. Management said the U.S. modern oral market exceeded £2bn of revenue in 2025 and that BAT reached global volume share leadership in top modern oral markets. Vapour remains attractive but more exposed to illicit competition and enforcement swings. Heated tobacco offers upside, but BAT’s share position there is less mature.
This market backdrop supports a balanced view on BTI. The company does not need booming industry growth to work as an investment. It needs stable combustible cash flow, continued pricing power, and enough share capture in modern oral, vapour, and heated products to improve mix over time. FY2025 showed progress on exactly those points.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
BAT serves adult nicotine consumers across a wide spectrum of preferences, price points, and regulatory environments. Its combustible portfolio covers premium, mid-tier, and value brands, while its New Categories portfolio targets consumers migrating toward vapour, heated products, and oral nicotine. That breadth matters because nicotine consumption is fragmenting, not disappearing.
The clearest customer signal in the supplied data is around modern oral behavior. Management said Velo Plus maintained a repurchase rate of around 70% throughout the year, brand awareness in the U.S. was around 30%, and average daily consumption rose from 2.8 pouches per day to 3.6. Management compared that with around 6 pouches per day in Europe and 12 in the Nordics. Those figures point to both retention and runway.
BAT’s customer profile is also increasingly premium in reduced-risk categories. Velo Shift trades at a premium to core Velo. Vuse Ultra is positioned as the flagship of the premium Vuse portfolio. glo Hilo is designed for the premium heated segment. This is not accidental. Premium users tend to be more profitable, more brand-sensitive, and less vulnerable to pure price competition.
In combustibles, the customer base is mature and structurally declining, but still economically valuable. BAT’s U.S. portfolio actions in Lucky Strike, Pall Mall Select, and Camel Black Series, combined with price-gap management and digital capabilities, helped drive a 4.6% increase in U.S. combustible revenue in 2025. That tells you the company still understands how to manage a shrinking category without surrendering value.
BAT competes primarily with Philip Morris International(PMI), Altria, and Imperial Brands. PMI is the strongest global benchmark in smoke-free execution, with about 43% of Q1 2026 net revenues coming from smoke-free products. Altria remains a formidable U.S. nicotine competitor through cigarettes, oral nicotine, and NJOY. Imperial is smaller but still relevant in combustibles and next-generation products.
BAT’s relative strength is breadth. It has major U.S. combustible brands such as Newport, Natural American Spirit, and Camel, plus global reduced-risk brands Vuse, glo, and Velo. That gives it a diversified portfolio across both cash-generation and transition categories. Its relative weakness is mix. New Categories were 11.7% of FY2025 revenue, which trails the smoke-free revenue mix of the strongest peer.
In modern oral, BAT’s position looks especially strong. Management said Velo is the clear European leader at around 6x the size of the nearest competitor and that BAT reached global volume share leadership in top modern oral markets. In the U.S., Velo Plus reached #2 in both volume and value share after launching at the end of 2024. Those are hard numbers, not branding poetry.
In vapour, BAT has a real asset in Vuse, but the market structure is messy. Illicit products in the U.S. and Canada have pressured category economics, though enforcement actions and a competitor exit helped Vuse return to revenue growth in H2 2025. In heated products, BAT is still building. glo Hilo and next-generation glo HYPER are credible attempts to strengthen the platform, but the company has more to prove here than in oral nicotine.
The bottom line is simple. BAT is not the undisputed winner in reduced-risk nicotine, but it is one of the few companies with the balance sheet, brands, science, distribution, and cash flow to stay in the fight globally. In this industry, survival with scale is already an advantage. Profitable share gains in modern oral make it more than that.
BAT operates in a sector where regulation matters more than GDP prints. Excise taxes, product approvals, flavor rules, marketing restrictions, and enforcement against illicit products all shape demand and profitability. In 2025, BAT said fiscal and regulatory headwinds in Bangladesh and Australia reduced total group revenue by around 1% and adjusted profit from operations by around 2%.
The U.S. regulatory backdrop is especially important for reduced-risk products. Management pointed to increased state-level enforcement, vapour directory legislation covering around 50% of tracked industry volume by year-end 2025, early signs of stronger federal enforcement, and a favorable initial determination from the International Trade Commission recommending a general exclusion order on imported illicit vapour devices. Those facts matter because Vuse’s recovery depends on a cleaner competitive field.
BAT also highlighted that the FDA has recognized the role nicotine pouches can play for adult smokers who would otherwise continue to smoke, and welcomed a pilot program to streamline PMTA review for nicotine pouches. That supports the modern oral thesis. Regulation in tobacco is rarely a tailwind, but in this case, tighter standards can favor scaled incumbents over gray-market operators.
Foreign exchange remains a real earnings variable. BAT cited transactional FX headwinds of about 1% on adjusted profit in 2025, driven mainly by Turkey, Japan, and Nigeria. For a global staples company with large non-U.S. earnings streams, reported numbers can look softer than underlying demand. That is one reason constant-currency revenue growth of 2.1% in FY2025 is more informative than the reported 1.0% decline.
Litigation and geopolitical exposure remain part of the investment case whether investors like it or not. The 20-F text references Canadian tobacco litigation, DOJ and OFAC investigation history, and Ukraine war conflict disclosures. Tobacco investing has never been a clean room. The right question is whether the cash flow compensates for the mess. At current multiples, BTI still argues that it does.
Net debt stands at $31.227bn against $3.843bn of cash, but adjusted net debt to adjusted EBITDA improved to 2.55x at year-end 2025.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →FY2025 revenue was £25.610bn and adjusted diluted EPS rose 3.4%, with gross margin at 82.7% and operating margin at 34.6%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management is guiding 2026 revenue growth of 3% to 5%, adjusted profit from operations growth of 4% to 6%, and adjusted diluted EPS growth of 5% to 8%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →BTI trades at about 12.6x trailing earnings and 12.2x forward earnings, alongside a 5.49% free cash flow yield and a 25-year dividend growth record.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value estimate is $68, with upside tied more to execution in Velo, Vuse, and glo than to multiple expansion.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →British American Tobacco(BTI) is not a clean growth story, and it is not meant to be. It is a high-margin, cash-heavy incumbent trying to turn a declining legacy franchise into a more durable nicotine platform. In 2025, that effort looked more credible than it had in several years.
The evidence is concrete: 34.1m smokeless consumers, 4.7m added in 2025, New Categories revenue up 7%, Modern Oral up 48%, category contribution at £442m, U.S. revenue up 5.5%, adjusted profit up 5.9%, and debt moving lower. At the same time, BTI still carries meaningful leverage, faces constant regulatory friction, and remains earlier in the smoke-free transition than the strongest peer.
That combination supports a balanced conclusion. BTI is attractive when priced like a fading tobacco stock but operating like a cash machine with a credible transition plan. With a fair value estimate of $68 and a Buy rating, the stock offers a sensible mix of income, defense, and medium-term upside, provided investors accept that this remains a regulated, controversial business where execution matters more than narrative.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
British American Tobacco p.l.c. (BTI) rises sharply as buyback support, stronger New Category momentum, and a favorable defensive-sector backdrop lift sentiment. The stock’s move stands out for a low-beta tobacco name, with investors still focused on income, valuation, and capital returns.
British American Tobacco offers a defensive income-and-value setup with strong cash flow, improving smokeless economics, and a Buy rating. The report highlights a 12.75x trailing P/E, rising New Categories contribution, and continued capital returns.
British American Tobacco p.l.c. (BTI) rises after a U.S. judge dismissed its criminal case tied to alleged North Korea sanctions violations. The rally reflects relief over a removed legal overhang, boosting confidence in BTI’s cash flow, dividend durability, and valuation as a defensive income stock.